Cefotaxime/sulbactam: clinical and pharmacological characteristics
| Autor: | A.V. Golub, E.A. Ortenberg |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2019 |
| Předmět: |
Microbiology (medical)
sulbactam Epidemiology business.industry cefotaxime/ sulbactam lcsh:QR1-502 Cefotaxime+Sulbactam Pharmacology lcsh:Microbiology lcsh:Infectious and parasitic diseases third-generation cephalosporins Infectious Diseases lower respiratory tract infections polycyclic compounds Medicine Pharmacology (medical) lcsh:RC109-216 antimicrobial resistance urinary tract infections business |
| Zdroj: | Клиническая микробиология и антимикробная химиотерапия, Vol 21, Iss 3, Pp 212-216 (2019) |
| ISSN: | 2686-9586 1684-4386 |
| Popis: | The recently approved cefotaxime/sulbactam, combination of third-generation cephalosporin (cefotaxime) and beta-lactamase inhibitor (sulbactam), can combat resistance mechanisms associated with the production of serine beta-lactamases, including some extended spectrum beta-lactamases. This paper reviews the use of this combination antibiotic in clinical practice based on the current data on antimicrobial resistance in pathogens causing lower respiratory tract infections and the results of completed clinical studies of its efficacy and safety. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|